Balancing novelty and validity, the role of probability in target identification, and discussing the role of the genetic links to disease indications.

Modeling multidimensional vascular networks is a notoriously difficult task, especially when considering the complex functions they perform within organ systems.

Thomas Hayhow, Associate Principal Scientist at AstraZeneca presents his company’s efforts in delivering PROTACs orally.

Recent developments in healthcare include the integration of AI chatbots in order to support primary care providers, offering improved patient care and efficiency in providing healthcare solutions.

Key opinion leaders from GSK and the University of Southampton discuss the steps needed to reach the lab of the future.

A Senior Director at AstraZeneca takes us through how the company synthesises and validates novel PROTACs.

The pharma industry is embracing digitalisation of the lab. Recent advancements in paperless technology and AI offer a peek into what the smart labs of the future will look like.

By taking a more holistic approach to the design of mobile robots, cleanroom automation and aseptic production in the manufacture of pharmaceutical therapeutics could be made into a reality.

Data digitisation has led to a market shift in operability, as well as a strong emphasis on trust and a need for broad standardisation. Zisis Kozlakidis, Head of Laboratory Services and Biobanking at the International Agency for Research on Cancer, sat down with us to discuss current and future trends in digital data governance for healthcare, as well as the need for a coordinated data strategy going forward.

Helping unlock the promise of Cellular Therapies and Regenerative Medicines

3D CoSeedisTM from abc biopply ag is a novel scaffold-free 3D cell co-culture system.

Lantern will use their artificial intelligence (AI) platform, RADR, to accelerate the development of ADC candidates from discovery to clinical trials within a timeframe of approximately two years.